Adamas Pharmaceuticals (NASDAQ:ADMS)‘s stock had its “buy” rating reiterated by equities research analysts at Northland Securities in a note issued to investors on Friday, AnalystRatings.com reports. They presently have a $15.00 price objective on the specialty pharmaceutical company’s stock. Northland Securities’ price objective would indicate a potential upside of 166.43% from the stock’s previous close.
Several other equities research analysts also recently commented on the company. Bank of America downgraded Adamas Pharmaceuticals from a “neutral” rating to an “underperform” rating and reduced their target price for the company from $9.00 to $5.00 in a report on Monday, September 30th. Cowen set a $5.00 target price on Adamas Pharmaceuticals and gave the company a “hold” rating in a report on Friday, August 9th. Cantor Fitzgerald initiated coverage on Adamas Pharmaceuticals in a report on Monday, September 9th. They set a “neutral” rating and a $8.00 target price for the company. Zacks Investment Research downgraded Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 16th. Finally, Evercore ISI reaffirmed a “buy” rating and set a $55.00 target price on shares of Adamas Pharmaceuticals in a report on Monday, August 12th. Three investment analysts have rated the stock with a sell rating, five have issued a hold rating and six have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and a consensus target price of $17.02.
NASDAQ:ADMS traded up $0.93 during midday trading on Friday, reaching $5.63. The stock had a trading volume of 1,119,200 shares, compared to its average volume of 491,521. The company has a quick ratio of 7.05, a current ratio of 7.27 and a debt-to-equity ratio of 3.05. The stock has a market cap of $119.97 million, a P/E ratio of -1.16 and a beta of 1.61. The firm has a fifty day simple moving average of $4.71 and a two-hundred day simple moving average of $5.53. Adamas Pharmaceuticals has a 12-month low of $3.35 and a 12-month high of $13.25.
A number of institutional investors have recently made changes to their positions in ADMS. Quantamental Technologies LLC purchased a new stake in Adamas Pharmaceuticals in the 2nd quarter worth about $25,000. Dowling & Yahnke LLC acquired a new position in Adamas Pharmaceuticals in the 3rd quarter worth about $66,000. Advisor Group Inc. increased its position in Adamas Pharmaceuticals by 53.4% in the 2nd quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock worth $69,000 after purchasing an additional 3,900 shares during the last quarter. DekaBank Deutsche Girozentrale increased its position in Adamas Pharmaceuticals by 63.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock worth $91,000 after purchasing an additional 6,000 shares during the last quarter. Finally, Wells Fargo & Company MN increased its position in Adamas Pharmaceuticals by 144.8% in the 2nd quarter. Wells Fargo & Company MN now owns 22,396 shares of the specialty pharmaceutical company’s stock worth $138,000 after purchasing an additional 13,247 shares during the last quarter. 63.22% of the stock is owned by hedge funds and other institutional investors.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Recommended Story: Resistance Level
Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.